Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes

  • Di Bonaventura C
  • Fattouch J
  • Mari F
 et al. 
  • 15


    Mendeley users who have this article in their library.
  • 34


    Citations of this article.


Clinical experience in open-label studies and anectodal reports suggest that levetiracetam is effective in generalized epilepsy. In this open-label prospective study, 19 patients (3 men, 16 women) affected by idiopathic generalized epilepsy were followed for at least 6 months following the introduction of levetiracetam. Patients were categorized according to syndrome subtype: juvenile myoclonic epilepsy (8), juvenile absence epilepsy (5), childhood absence epilepsy (4), and eyelid myoclonia with absences (2). Eleven patients received levetiracetam as monotherapy, eight as add-on therapy. Effectiveness was demonstrated in 18 patients: 13 became seizure-free (five juvenile myoclonic epilepsy, five juvenile absence epilepsy, three childhood absence epilepsy), and five achieved significant reductions in seizure frequency (three juvenile myoclonic epilepsy, one childhood absence epilepsy, one eyelid myoclonia with absences). Only one patient experienced no change in seizure frequency (eyelid myoclonia with absences). Clinical improvement was accompanied by EEG abnormality suppression or reduction. Levetiracetam was well tolerated; no patient reported side-effects.

Author-supplied keywords

  • Add-on therapy
  • Idiopathic generalized epilepsy
  • Juvenile myoclonic epilepsy
  • Levetiracetam
  • Monotherapy

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Carlo Di Bonaventura

  • Jinane Fattouch

  • Francesco Mari

  • Gabriella Egeo

  • Massimiliano Prencipe

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free